AWM
ORIC icon

Avior Wealth Management’s Oric Pharmaceuticals ORIC Stock Holding History

Avior Wealth Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$110 – 3266
2024
Q1 		$110 Buy
+8
New +$95 ﹤0.01% 3148

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avior Wealth Management's ORIC Position: Q2 2024 in Review

Avior Wealth Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2024, closing a stake of 8 shares — an estimated $110 sold.

Avior Wealth Management first reported a position in ORIC in Q1 2024 and held it in 1 quarter. The position peaked at $110 in Q1 2024. 113 funds tracked by Wall St. Rank hold ORIC as of Q2 2024.

  • Avior Wealth Management reported no remaining Oric Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 8 Oric Pharmaceuticals shares in Q2 2024, an estimated $110.
  • Avior Wealth Management first reported a position in Oric Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Oric Pharmaceuticals position peaked at $110 in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.